Thursday, May 7, 2026

2026 MedTech Spotlight: How Korea’s Medical Device Industry is Shaping Global Partnerships

South Korea's MedTech Spotlight event fosters global collaboration, emphasizing proactive partnerships and market strategies for medical devices.

China and North Korea Mark 80th Victory Day, Pledging to Bolster ‘Blood Alliance’

The Chinese Embassy in North Korea celebrated the 80th Victory Day, emphasizing the strong ties between China and North Korea.

South Korea and China’s Defense Dialogue: What’s on the Table?

On June 18, Senior diplomatic and defense...

Health

CG Bio Group Launches Acellular Dermal Matrix-based Product Reallo Inject Fine

CG Bio launches Reallo Inject Fine, an acellular dermal matrix product, enhancing usability for medical professionals and expanding applications.

Ceragem Launches Global Standard for AI Home Healthcare, Accelerates Data Platform Push

Ceragem's new ISO/IEC report sets international standards for integrating home healthcare devices, focusing on user well-being and safety.

Hugel Participates AMWC ASIA & TDAC 2026 at the Taipei International Convention Center, Taiwan

Hugel targets Taiwan's aesthetic market, showcasing products at AMWC ASIA & TDAC 2026, while expanding in Indonesia with educational programs.

L&K BioMed Showcases Innovative Products at the AANS Conference in Texas

L&K BioMed showcased its products at the AANS conference, receiving positive feedback and interest for its cervical products, aiming to expand in the U.S. market.

Seers Signs $14.7 Million Contract with UAE to Supply 105,000 Units over 3 Years

Seers signs a major deal for mobiCARE devices in the UAE, aiming for 50% growth and expansion into Vietnam and beyond.

GAME OVER: Samsung Biologics Declares War With ‘ExellenS’—A Standard That Kills All Biotech Competition

Samsung Biologics launches ExellenS in Europe, enhancing biopharmaceutical production with standardized quality and efficiency.

Chinese & Indian Medical Invasion: Pharmaceutic Dependency on Risk of Essential Medicine Supply

Concerns rise over South Korea's API industry reliance on China and India, with self-sufficiency at a record low of 25.6% in 2023.

Samsung Biologics Targets Japan’s $12.3 Billion CDMO Market: What You Need to Know

Samsung Biologics expands in Japan, targeting top pharma firms with new CMO brand 'ExellenS' and enhancing production capabilities.

Lotte Biologics Unveils Dual-Site Strategy: A Game Changer for Global CDMO in 2027

Lotte Biologics aims to lead in the evolving biotech landscape with dual sites in the U.S. and South Korea, enhancing global supply chains.

From R&D to Global Blockbuster: Fexuclue Sparks a New Vision for Daewoong

Daewoong Pharmaceutical's Fexuclue achieves rapid success with innovative marketing and aims for significant growth in treating GERD.

Fever’s Bigger Risk: Why the Tylenol Controversy Puts Moms in a Bind

Controversy surrounds acetaminophen use during pregnancy and its alleged link to autism, but evidence remains inconclusive.

Is Tylenol Dangerous for Pregnant Women? Trump’s Controversial Claims Debunked by Experts

UK Health Secretary counters Trump's claim linking Tylenol to autism, affirming its safety for pregnant women based on scientific studies.

Trump’s Next Target: Big Pharma’s Tylenol. Why He’s Questioning a $1B Industry

Trump links Tylenol to autism risk, announcing new FDA guidelines and studies, but scientific consensus remains unestablished.

Celltrion’s ‘Psoriasis’ Biosimilar Poised to Challenge Big Pharma with Phase 1 Data

The EADV conference in Paris showcased Celltrion's biosimilar CT-P55, confirming its equivalence to Cosentyx in safety and pharmacokinetics.

Bio-Revolution: Celltrion’s $700M Biosimilar Is Reshaping the Global Drug Market

Celltrion's breakthrough in antibody biosimilars is transforming healthcare, enhancing access and innovation in treatment options.

Sales and Trust: How Celltrion is Revolutionizing the European Market Directly Connected

Celltrion leverages direct sales in Europe to enhance trust and supply stability while introducing biosimilars like Omlyclo for asthma treatment.

Tylenol Stock Plunges: Trump’s Autism Warning Rattles $17B Market

Tylenol faces scrutiny over potential autism link during pregnancy, with mixed responses from the medical community and FDA caution.

Celltrion’s Biosimilar Success in Europe Paves the Way for a US Market Takeover

Celltrion's booth at EADV 2025 highlighted biosimilar innovations, showcasing promising clinical trial results and expanding treatment access.

Biosimilars No Longer Second-Best: Highlighting Cost Savings and Improved Patient Access

Biosimilars are becoming standard care, with growing confidence in their safety and efficacy, driven by cost savings and improved accessibility.

Top News

- Our Sponsors Ad -

Follow us